Ryan C Lynch1,2,3, Vandana Sundaram4, Manisha Desai4, Solomon Henry5, Douglas Wood5, Sarah Daadi6, Richard T Hoppe7, Ranjana Advani8. 1. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. 2. Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Division of Oncology, Department of Medicine, Stanford University, Stanford, CA. 4. Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA. 5. Stanford University School of Medicine, Stanford, CA. 6. Stanford Cancer Institute, Stanford, CA. 7. Department of Radiation Oncology, Stanford University, Stanford, CA. 8. Department of Medicine, Stanford University, Stanford, CA.
Abstract
PURPOSE: Classic Hodgkin lymphoma is highly curable with contemporary therapy. Although the limited role of surveillance imaging to detect early relapse for patients in complete remission at the end of therapy is well established, there is a paucity of data regarding role of laboratory testing in this setting. METHODS: Patients with newly diagnosed classic Hodgkin lymphoma uniformly treated with the Stanford V regimen from 1998-2014 and in complete remission for at least 3 months were identified in a single-center institutional database. Laboratory tests categorized by Common Terminology Criteria for Adverse Events v4.03 as grade 2 or higher were considered abnormal. Primary analysis included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of surveillance laboratory tests for predicting relapse in the first 3 years after end of treatment. RESULTS: Among 235 eligible patients, 24 (10.2%) patients ultimately relapsed. In the first 3 years after end of therapy, the mean number of surveillance blood draws per patient was 7.1, (range, 1-13). These 1,661 surveillance blood draws included 4,684 individual laboratory tests, comprising 1,609 CBCs, 1,578 metabolic panels, and 1,497 erythrocyte sedimentation rates. None of the biopsies confirming relapses were prompted by any abnormal laboratory finding. The sensitivity of any surveillance laboratory test for detecting relapse within 3 years of end of treatment was 72.7% (95% CI, 49.8% to 89.3%), specificity 22.6% (95% CI, 17.2% to 28.9%), yielding a PPV of 8.9% (95% CI, 7.0% to 11.3%) and NPV of 88.9% (95% CI, 79% to 94%). CONCLUSION: Our study found limited clinically meaningful utility for routine surveillance laboratory testing in detecting relapse in patients with complete remission at end of treatment. Our results warrant consideration of modifications to current practice guidelines.
PURPOSE: Classic Hodgkin lymphoma is highly curable with contemporary therapy. Although the limited role of surveillance imaging to detect early relapse for patients in complete remission at the end of therapy is well established, there is a paucity of data regarding role of laboratory testing in this setting. METHODS: Patients with newly diagnosed classic Hodgkin lymphoma uniformly treated with the Stanford V regimen from 1998-2014 and in complete remission for at least 3 months were identified in a single-center institutional database. Laboratory tests categorized by Common Terminology Criteria for Adverse Events v4.03 as grade 2 or higher were considered abnormal. Primary analysis included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of surveillance laboratory tests for predicting relapse in the first 3 years after end of treatment. RESULTS: Among 235 eligible patients, 24 (10.2%) patients ultimately relapsed. In the first 3 years after end of therapy, the mean number of surveillance blood draws per patient was 7.1, (range, 1-13). These 1,661 surveillance blood draws included 4,684 individual laboratory tests, comprising 1,609 CBCs, 1,578 metabolic panels, and 1,497 erythrocyte sedimentation rates. None of the biopsies confirming relapses were prompted by any abnormal laboratory finding. The sensitivity of any surveillance laboratory test for detecting relapse within 3 years of end of treatment was 72.7% (95% CI, 49.8% to 89.3%), specificity 22.6% (95% CI, 17.2% to 28.9%), yielding a PPV of 8.9% (95% CI, 7.0% to 11.3%) and NPV of 88.9% (95% CI, 79% to 94%). CONCLUSION: Our study found limited clinically meaningful utility for routine surveillance laboratory testing in detecting relapse in patients with complete remission at end of treatment. Our results warrant consideration of modifications to current practice guidelines.
Authors: D A Eichenauer; B M P Aleman; M André; M Federico; M Hutchings; T Illidge; A Engert; M Ladetto Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Philippe Armand; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Robert Chen; Bouthaina Dabaja; Robert Dean; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Mark S Kaminski; Vaishalee P Kenkre; Nadia Khan; Kami Maddocks; David G Maloney; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Rachel Rabinovitch; Stuart Seropian; Randa Tao; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Ndiya Ogba Journal: J Natl Compr Canc Netw Date: 2018-03 Impact factor: 11.908
Authors: Marc P E André; Théodore Girinsky; Massimo Federico; Oumédaly Reman; Catherine Fortpied; Manuel Gotti; Olivier Casasnovas; Pauline Brice; Richard van der Maazen; Alessandro Re; Véronique Edeline; Christophe Fermé; Gustaaf van Imhoff; Francesco Merli; Réda Bouabdallah; Catherine Sebban; Lena Specht; Aspasia Stamatoullas; Richard Delarue; Valeria Fiaccadori; Monica Bellei; Tiana Raveloarivahy; Annibale Versari; Martin Hutchings; Michel Meignan; John Raemaekers Journal: J Clin Oncol Date: 2017-03-14 Impact factor: 44.544
Authors: Vatsal Patel; Michael Buckstein; Rodolfo Perini; Christine Hill-Kayser; Jakub Svoboda; John P Plastaras Journal: Leuk Lymphoma Date: 2013-02-12
Authors: Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: R H Advani; R T Hoppe; D Baer; J Mason; R Warnke; J Allen; S Daadi; S A Rosenberg; S J Horning Journal: Ann Oncol Date: 2012-11-07 Impact factor: 32.976